# EDGAR Filing Document

**Accession Number:** 0001445815
**File Stem:** 0001493152-25-027639
**Filing Date:** 2025-12
**Character Count:** 6228
**Document Hash:** f057c280a648e945efda415955cb164c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-027639.hdr.sgml**: 20251215

**ACCESSION NUMBER**: 0001493152-25-027639

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251207

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251215

**DATE AS OF CHANGE**: 20251215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOXYTRAN, INC
- **CENTRAL INDEX KEY:** 0001445815
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262797630
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35027
- **FILM NUMBER:** 251569925

**BUSINESS ADDRESS:**
- **STREET 1:** C/O BIOXYTRAN, INC.
- **STREET 2:** 75 2ND AVE, SUITE 605 STE 605
- **CITY:** NEEDHAM
- **STATE:** MA
- **ZIP:** 02494
- **BUSINESS PHONE:** 617-494-1199

**MAIL ADDRESS:**
- **STREET 1:** C/O BIOXYTRAN, INC.
- **STREET 2:** 75 2ND AVE, SUITE 605 STE 605
- **CITY:** NEEDHAM
- **STATE:** MA
- **ZIP:** 02494

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** U.S. RARE EARTH MINERALS, INC.
- **DATE OF NAME CHANGE:** 20181005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** U.S. RARE EARTH MINERALS, INC
- **DATE OF NAME CHANGE:** 20110512

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** U.S. Natural Nutrients & Minerals, Inc.
- **DATE OF NAME CHANGE:** 20091029

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): December 7, 2025**

**BIOXYTRAN, INC.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-35027** | **26-2797630** |
| (State or Other Jurisdiction | (Commission | (IRS Employer |
| of Incorporation) | File Number) | Identification Number) |

---

---

| | |
|:---|:---|
| **75 Second Ave, Suite 605, Needham, MA** | **02494** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code **617-454-1199**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 | BIXT | OTCQB |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On December 7, 2025, Anders Utter notified Bioxytran, Inc. (the "Company") that he was resigning from the Company's Board of Directors and as Chair of the Audit Committee, effective immediately.

In his resignation letter, Mr. Utter noted that he had recommended enhancements to the Company's oversight framework, internal controls, and approval processes. These recommendations included strengthening segregation of duties, improving documentation of material contractual and financial approvals, and conducting legal review of a recently completed stock issuance. Mr. Utter stated that certain recommendations were not adopted or were interpreted differently than intended, and that he believed greater alignment on governance practices was needed. In response to these concerns, the Company has engaged an independent third-party financial expert to review its oversight, internal control, and approval processes. The expert will provide recommendations to the Board, and, if approved, assist in implementing the procedures.

Mr. Utter did not cite any disagreement relating to the Company's financial statements, accounting practices, or disclosures in its SEC filings. Pursuant to SEC rules, the Company has provided Mr. Utter with a copy of this disclosure and offered him the opportunity to provide a letter stating whether he agrees with the Company's description of his resignation. If received, the Company will file such letter by amendment to this Form 8-K.

The Board thanks Mr. Utter for his service and contributions.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | BIOXYTRAN, INC. | BIOXYTRAN, INC. |
|  | By: | */s/ David Platt, Ph.D.* |
|  |  | David Platt, Ph.D., its Chief Executive Officer |
| Date December 15, 2025 |  |  |

---